Biotech Genocea Biosciences files for a $75 million IPO

By
A A A
Share |

Genocea Biosciences, which is developing novel vaccines for infectious diseases through T cell immune responses, filed on Monday with the SEC to raise up to $75 million in an initial public offering. Venture backers include Polaris Venture Partners (16% pre-IPO stake), Lux Ventures (15%), S.R. One (13%), Johnson & Johnson (12%), CVF, an affiliate of Henry Crown and Company (9%), Skyline Venture Partners (9%), Cycad Group (7%), Auriga Ventures (7%) and Bill & Melinda Gates Foundation (6%).

The Cambridge, MA-based company, which was founded in 2006, plans to list on the NASDAQ under the symbol GNCA. Genocea Biosciences initially filed confidentially on October 22, 2013. Citi and Cowen & Company are the lead bookrunners on the deal. No pricing terms were disclosed.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: GNCA

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

89,970,926
  • $16.15 ▲ 0.12%
77,131,582
  • $58.94 ▼ 1.31%
67,336,935
  • $26.56 ▲ 1.68%
48,814,124
  • $86.20 ▲ 0.02%
47,526,126
  • $23.21 ▲ 0.78%
44,660,424
  • $23.91 ▲ 6.36%
38,799,699
  • $4.289 ▲ 4.36%
36,199,890
  • $40.01 ▼ 0.97%
As of 4/17/2014, 04:07 PM